Skip to main content
Tianjin Ringpu Bio-Technology Co.,Ltd. logo

Tianjin Ringpu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 300119 ISIN · CNE100000TV1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,284 across all filing types
Latest filing 2023-06-26 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300119

About Tianjin Ringpu Bio-Technology Co.,Ltd.

https://www.ringpu.com

Tianjin Ringpu Bio-Technology Co.,Ltd. is a high-tech enterprise specializing in the research, development, production, and sale of animal health products. The company offers a comprehensive portfolio that includes veterinary biological products, chemical drugs, feed additives, and pet health solutions. Its product range covers vaccines for poultry and livestock, as well as various pharmaceutical formulations such as injections, powders, and oral solutions. Ringpu Bio-Technology emphasizes innovation through its dedicated R&D centers, focusing on disease prevention and treatment to support the global animal husbandry industry. The company provides integrated health management services and high-quality veterinary medicines to ensure food safety and animal welfare.

Recent filings

Filing Released Lang Actions
关于签署战略合作框架协议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Tianjin Ruipu Biotechnology Co., Ltd. about signing a strategic cooperation framework agreement with another company. It details the nature of the cooperation, the parties involved, the scope of the agreement, and the expected impact on the company. There is no financial data, no quarterly or annual report content, no audit information, no voting results, no executive changes, and no earnings release. The document is a formal announcement of a strategic cooperation agreement, which is a type of corporate transaction update but does not fit into M&A or capital financing categories. It is not a report but an announcement of a corporate event. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories. The document length is under 5,000 characters, and it is a standalone announcement, not a report or presentation.
2023-06-26 Chinese
关于回购注销部分限制性股票通知债权人的公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement by Tianjin Ruipu Biotechnology Co., Ltd. regarding the repurchase and cancellation of part of its restricted stock. It details the board and shareholder meeting approvals, the number of shares to be repurchased and cancelled, the impact on total share capital, and a notification to creditors about their rights to claim debts or request guarantees within 45 days. The document is a formal notice to creditors about the company's stock repurchase and capital reduction, not a financial report or earnings release. It does not contain financial statements or detailed financial data but serves as a regulatory announcement related to share repurchase and capital change. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA). The document length is short (1596 characters), and it is not merely an announcement of a report but a substantive announcement about capital change.
2023-06-26 Chinese
2023年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2023 first extraordinary general meeting (临时股东大会) of Tianjin Ruipu Biotechnology Co., Ltd. It details the meeting attendance, voting procedures, and voting results on specific proposals such as the repurchase and cancellation of restricted stock and amendments to the company articles. It also includes a legal opinion confirming the legality of the meeting and voting process. The document is not a full report but an official announcement of voting results from a shareholders meeting. The document length is under 5,000 characters and it primarily reports voting outcomes rather than financial data or management discussion. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-06-26 Chinese
独立董事对第五届董事会第六次（临时）会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters discussed at a board meeting, specifically regarding the repurchase and cancellation of restricted stock under a 2022 stock incentive plan and the adjustment of the repurchase price. It references compliance with stock exchange rules and company procedures. The content focuses on board-level approval and opinions rather than financial results or detailed financial statements. It is not a full annual or interim report, nor an earnings release or audit report. It is also not a regulatory filing or announcement of a report publication. The document fits best under Board/Management Information (MANG) as it relates to board decisions and management-level corporate governance matters.
2023-06-09 Chinese
第五届监事会第六次（临时）会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Tianjin Ruipu Biotechnology Co., Ltd. It details the meeting held on June 9, 2023, including decisions on the repurchase and cancellation of restricted stock under the 2022 stock incentive plan and adjustments to the repurchase price. The document includes voting results and references to further announcements on the Shenzhen Stock Exchange and CNINFO websites. It is not a full financial report, audit, or earnings release, nor is it a shareholder meeting material or voting result declaration. It is a formal announcement of board-level decisions related to stock incentive plans, which fits best under Board/Management Information (MANG). The document length is short and focused on management decisions rather than financial data or regulatory filings, supporting this classification.
2023-06-09 Chinese
北京市康达律师事务所关于天津瑞普生物技术股份有限公司回购注销2022年限制性股票激励计划部分限制性股票及调整回购价格的法律意见书
Transaction in Own Shares Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the repurchase and cancellation of restricted stock under a 2022 stock incentive plan and the adjustment of the repurchase price. It details the legal basis, approvals, and specific terms related to the stock repurchase and cancellation. It is not a financial report, earnings release, or regulatory filing about financial results. Instead, it is a legal opinion related to a corporate action involving stock repurchase and cancellation. This type of document does not fit into categories like 10-K, IR, ER, or CAP directly. It is a specialized legal opinion on a stock repurchase and cancellation matter, which aligns best with the category Transaction in Own Shares (POS), as it concerns the company's repurchase and cancellation of its own shares under a stock incentive plan.
2023-06-09 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.